ArteraAI, a San Francisco, CA-based developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, raised additional $20M in funding.
The round saw participation from Prosperity7 Ventures, Singapore-based global investor EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures, along with investors Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC).
The company intends to use the funds for the international expansion and commercial growth of the company and its test.
Led by Andre Esteva, CEO, ArteraAI is a precision medicine company developing AI tests to personalize cancer therapy to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test. Its multimodal artificial intelligence (MMAI) biomarker test leverages an algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis and has been validated using many Phase 3 randomized trials.
The test is clinically available through our CLIA-certified laboratory in Jacksonville, Florida.
Commenting on the news, Andre Esteva said: “The infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and prognostic tests.”
FinSMEs
01/02/2024